Status:
UNKNOWN
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
Lead Sponsor:
Far Eastern Memorial Hospital
Conditions:
Overactive Bladder Syndrome
Eligibility:
FEMALE
20+ years
Phase:
PHASE3
Brief Summary
To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and bladder blood flow.
Detailed Description
To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and blood flow.
Eligibility Criteria
Inclusion
- Overactive bladder syndrome
Exclusion
- Allergy to mirabegron or solifenacin.
- Patients with severe hypertension who are difficult to control, known urethral diverticulum, known bladder malignant tumors, urinary retention patients, gastric retention patients, uncontrolled angular glaucoma patients, dialysis patients, severe renal dysfunction , moderate liver dysfunction, use strong inhibitors of CYP3A4 such as ketoconazole.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04023253
Start Date
August 1 2019
End Date
December 31 2024
Last Update
September 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan, 22050